Migraine is a disabling neurologic disease that can fluctuate over time in severity, frequency, and acute medication use. Harris Poll Migraine Report Card was a US population-based survey to ascertain quantifiable distinctions amongst individuals with current versus previous high-frequency headache/migraine and acute medication overuse (HFM+AMO). The objective of this report is to compare self-reported experiences in the migraine journey of adults with HFM+AMO to those who previously experienced HFM+AMO but currently have a sustained reduction in headache/migraine frequency and acute medication use. An online survey was available to a general population panel of adults (≥18 years) with migraine per the ID Migraine™ screener. Respondents were classified into “current HFM+AMO” (within the last few months had ≥8 headache days/month and ≥10 days/month of acute medication use; n=440) or “previous HFM+AMO” (previously had HFM+AMO, but within the last few months had ≤7 headache days/month and ≤9 days/month of acute medication use; n=110). Survey questions pertained to demographics, diagnosis, living with migraine, healthcare provider (HCP) communication, and treatment. Participants in the current HFM+AMO group had 15.2 monthly headache days and 17.4 days of monthly acute medication use in last few months compared to 4.2 and 4.1 days for the previous HFM+AMO group, respectively. Overall, current preventive pharmacologic treatment use was low (15-16%; P>0.1 for current vs previous) in both groups. Previous HFM+AMO respondents reported better current acute treatment optimization. More respondents with current (80%) than previous HFM+AMO (66%) expressed concern with their current health (P<0.05). More than one-third of both groups wished their HCP better understood their mental/emotional health (current 37%, previous 35%; P>0.1 for current vs previous) and 47% (current) to 54% (previous) of respondents worried about asking their HCP too many questions (P>0.1 for current vs previous). Apart from optimization of acute medication, medical interventions did not significantly differentiate between the current and previous HFM+AMO groups. Use of preventive pharmacological medication was low in both groups. Adults with current HFM+AMO more often had health concerns, yet both groups expressed concerns of disease burden. Optimization of acute and preventive medication and addressing mental/emotional health concerns of patients are areas where migraine care may impact outcomes regardless of their disease burden.

中文翻译：

---

哈里斯民意调查偏头痛报告卡：基于人群的高频头痛/偏头痛和急性药物过度使用检查

偏头痛是一种致残性神经系统疾病，其严重程度、频率和急性药物使用情况会随着时间的推移而波动。哈里斯民意调查偏头痛报告卡是一项以美国人口为基础的调查，旨在确定当前与既往高频头痛/偏头痛和急性药物过度使用 (HFM+AMO) 患者之间的可量化差异。本报告的目的是将患有 HFM+AMO 的成人自我报告的偏头痛经历与那些之前经历过 HFM+AMO 但目前头痛/偏头痛频率和急性药物使用持续减少的人进行比较。根据 ID Migraine™ 筛查仪，可对患有偏头痛的一般成人（≥18 岁）人群进行在线调查。受访者被分为“当前 HFM+AMO”（过去几个月内头痛天数/月≥8 天且急性药物使用天数/月≥10 天；n=440）或“既往 HFM+AMO”（之前有 HFM+ AMO，但在过去几个月内头痛天数≤7 天/月，急性药物使用天数≤9 天/月；n=110)。调查问题涉及人口统计、诊断、偏头痛生活、医疗保健提供者 (HCP) 沟通和治疗。当前 HFM+AMO 组的参与者在过去几个月中每月头痛天数为 15.2 天，每月急性药物使用天数为 17.4 天，而之前的 HFM+AMO 组分别为 4.2 天和 4.1 天。总体而言，两组当前预防性药物治疗的使用率较低（15-16%；当前与之前相比 P>0.1）。以前的 HFM+AMO 受访者报告了目前更好的急性治疗优化。当前有 HFM+AMO 的受访者 (80%) 比以前有 HFM+AMO (66%) 的受访者更多地表达了对当前健康状况的担忧 (P<0.05)。两组中超过三分之一的人希望他们的 HCP 更好地了解自己的心理/情绪健康状况（当前为 37%，以前为 35%；当前与以前相比 P>0.1），47%（当前）至 54%（以前）的受访者表示担心关于向 HCP 询问太多问题（当前与之前相比 P>0.1）。除了优化急性药物治疗外，医疗干预措施在当前和之前的 HFM+AMO 组之间没有显着差异。两组中预防性药物的使用率都较低。目前患有 HFM+AMO 的成年人更常有健康问题，但两组都表达了对疾病负担的担忧。优化急性和预防性药物治疗以及解决患者的精神/情绪健康问题是偏头痛护理可能影响结果的领域，无论其疾病负担如何。